Novel First-in-Class Drugs

Cleave Biosciences has a pipeline of novel, first-in-class therapeutics targeting protein degradation pathways for difficult to treat cancers and neurodegenerative diseases, as well as a deep understanding of the underlying biology of these pathways.

Inquiries related to potential partnering opportunities can be directed to info@cleavebio.com.